Our results show that IO can induce the decreased number and osteogenic differentiation ability of MSCs from MDS patients, and impair the proliferation ability of MSCs by affecting the AkT-related signaling pathway. This evidence concerns the gene AKT1 and myelodysplastic syndrome.